PT  - JOURNAL ARTICLE
AU  - Keith A. Johnson
AU  - Satoshi Minoshima
AU  - Nicolaas I. Bohnen
AU  - Kevin J. Donohoe
AU  - Norman L. Foster
AU  - Peter Herscovitch
AU  - Jason H. Karlawish
AU  - Christopher C. Rowe
AU  - Saima Hedrick
AU  - Virginia Pappas
AU  - Maria C. Carrillo
AU  - Dean M. Hartley
TI  - Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education
AID  - 10.2967/jnumed.113.127068
DP  - 2013 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 1011--1013
VI  - 54
IP  - 7
4099  - http://jnm.snmjournals.org/content/54/7/1011.short
4100  - http://jnm.snmjournals.org/content/54/7/1011.full
SO  - J Nucl Med2013 Jul 01; 54
AB  - Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.